OncoMatch/Clinical Trials/NCT06890884
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Is NCT06890884 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for lymphoma, large b-cell, diffuse.
Treatment: Zilovertamab vedotin · Rituximab · Cyclophosphamide · Doxorubicin · Rituximab Biosimilar · Prednisone · Prednisolone · Polatuzumab vedotin · Rescue Medication — Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Excluded: Stage ANN ARBOR STAGE I
Has Ann Arbor Stage I DLBCL [excluded]
Prior therapy
Cannot have received: stem cell transplant
Has history of stem cell/solid organ transplant
Cannot have received: solid organ transplant
Has history of stem cell/solid organ transplant
Lab requirements
Cardiac function
No clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication
Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Infirmary Cancer Care ( Site 0157) · Mobile, Alabama
- Palo Verde Cancer Specialists ( Site 0105) · Glendale, Arizona
- Genesis Cancer and Blood Institute ( Site 0193) · Hot Springs, Arkansas
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135) · Burbank, California
- Bass Medical Group ( Site 0123) · Walnut Creek, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify